manufacturing · health · energy · biology · family: the model was never trained on this
the microbe thrives in the flask, dies in the tank
Engineered biological systems that work in flasks fail unpredictably at bioreactor scale
Problem statement
Biomanufacturing — using engineered microorganisms, cell cultures, or enzymatic processes to produce chemicals, materials, and therapeutics — runs into what the NSF Future Manufacturing solicitation calls "longstanding barriers to scalability" when a process moves from laboratory flasks to production bioreactors. Organisms engineered to produce target molecules at high yields in well-mixed, well-aerated shake flasks experience fundamentally different conditions at scale: heterogeneous dissolved oxygen, pH and nutrient gradients, shear stress from impellers, and metabolic byproduct accumulation. Predicting which laboratory-validated bioprocesses will fail at scale, and why, remains the open problem; the solicitation asks for research that will "facilitate rapid transition from benchtop to production readiness."
Why this matters
The 2022 Executive Order on Advancing Biotechnology and Biomanufacturing Innovation calls for expanding domestic biomanufacturing capacity across health, energy, agriculture, and industrial sectors. Biomanufactured products — the NSF solicitation lists chemicals, pharmaceuticals, materials, polymers, and fuels — are tied in the Executive Order to climate and energy goals, including reducing greenhouse gas emissions. The Executive Order names the gap directly: among the foundational capabilities the United States needs to invest in, it lists the need to "advance the science of scale-up production while reducing the obstacles for commercialization so that innovative technologies and products can reach markets faster."
What’s been tried and why it hasn’t worked
Traditional chemical engineering scale-up relies on dimensionless numbers (Reynolds, Damkohler) to maintain similarity across scales, but biological systems violate the assumptions behind these correlations — cells are not passive reactants but adaptive organisms that change their gene expression, metabolism, and growth behavior in response to environmental shifts. Scale-down models that replicate large-scale heterogeneity in laboratory bioreactors capture some failure modes but miss others because the temporal dynamics of gradient exposure differ. Computational fluid dynamics (CFD) coupled with metabolic models can simulate bioreactor conditions but require organism-specific kinetic parameters that are expensive to measure and often unreliable. High-throughput minibioreactors (ambr, BioLector) enable parallel screening of conditions but don't replicate the spatial heterogeneity that causes scale-up failures. Genome-scale metabolic models predict steady-state yields but not dynamic responses to the fluctuating conditions cells experience in large bioreactors.
What would unlock progress
A predictive framework integrating computational fluid dynamics, genome-scale metabolic modeling, and dynamic gene regulation models that can simulate organism behavior under the heterogeneous, time-varying conditions of industrial bioreactors. Machine learning models trained on paired small-scale/large-scale process data could identify early warning signatures of scale-up failure. Standardized protocols for characterizing organism responses to controlled environmental perturbations (oxygen shifts, pH pulses, shear steps) would generate the training data such models require.
Entry points for student teams
The computational door needs a laptop and no organism: couple open-source CFD (OpenFOAM, https://openfoam.org) to a published genome-scale metabolic model — E. coli iML1515 downloads free from BiGG Models (http://bigg.ucsd.edu/models/iML1515) and runs in COBRApy (https://opencobra.github.io/cobrapy/) — simulate the dissolved-oxygen and substrate gradients of a stirred tank, then ask how much predicted productivity is lost when cells are carried along those concentration trajectories instead of held at flask conditions. The wet-lab door should be deliberately narrow: impose oscillating dissolved oxygen on E. coli or S. cerevisiae in a benchtop fermenter and track growth, oxygen uptake, and acetate or ethanol accumulation — one perturbation, one readout — rather than attempting transcriptomics and metabolomics in the same term, which is three projects in one. That version takes a benchtop bioreactor and BSL-1 culture space, access most chemical- or bio-engineering departments that teach a bioprocess course already hold; the omics layers are the follow-on project once the perturbation protocol is stable. Relevant disciplines include bioengineering, chemical engineering, computational biology, and data science.
Genes
Structural cousins: stuck the same way, in other fields
Sources
NSF Future Manufacturing (FM) Program (NSF 24-525), Division of Civil, Mechanical and Manufacturing Innovation; accessed 2026-02-15; Executive Order on Advancing Biotechnology and Biomanufacturing Innovation (2022) go to source ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
The NSF Future Manufacturing program identifies biomanufacturing as one of its core thrust areas, with the stated goal of supporting "fundamental research, education, and training of a future workforce to overcome scientific, technological, educational, economic, and social barriers in order to catalyze new manufacturing capabilities that do not exist today." The 2022 Executive Order specifically targets expanding domestic biomanufacturing capacity. The NSF FM awards announced June 24, 2025 included projects on "bioengineering in resource-constrained environments." Related problems: manufacturing-am-metal-part-qualification-barrier.md shares the theme of lab-to-production qualification challenges in a different manufacturing domain. The ENG/CBET Cellular and Biochemical Engineering program also supports fundamental bioprocess research.
Reconciliation 2026-08-21: Entry-point triage flagged the scale-down-bioreactor door as three projects in one (custom reactor build + transcriptomics + metabolomics, all inside a facility) — the flag holds. Repair follows the triage recommendation: the computational door now leads and carries the brief as the facility-free entry, and the wet-lab door is narrowed to a single perturbation with a single readout plus an explicit access line (benchtop bioreactor, BSL-1 space, held by departments teaching bioprocess engineering), with the omics layers named as a follow-on. Resources verified live 2026-08-21 by fetch: OpenFOAM, free GPL download (https://openfoam.org); COBRApy, pip-installable and GPL (https://opencobra.github.io/cobrapy/); BiGG Models entry for E. coli iML1515, downloadable without an account (http://bigg.ucsd.edu/models/iML1515 — note the site answers on http; its https endpoint refused connection on the day of checking, so the http form is cited deliberately). Whole-section check against the ≥2-door rule: the computational door was already reachable and unflagged, so this brief did not carry the zero-reachable-door defect; no other door needed repair.
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against every source it names. Fetched 2026-09-30 and read in full: the NSF Future Manufacturing program page (https://www.nsf.gov/funding/opportunities/fm-future-manufacturing) and the NSF 24-525 solicitation it links to (https://www.nsf.gov/funding/opportunities/fm-future-manufacturing/nsf24-525/solicitation); Executive Order 14081 of September 12, 2022, from the Federal Register (https://www.federalregister.gov/documents/2022/09/15/2022-20167/advancing-biotechnology-and-biomanufacturing-innovation-for-a-sustainable-safe-and-secure-american-bioeconomy) and the archived White House copy; the NSF news release on the 2025 FM awards (https://www.nsf.gov/news/nsf-invests-255m-research-drive-new-us-manufacturing); the NSF Cellular and Biochemical Engineering program page; and the three entry-point pages (OpenFOAM, COBRApy, BiGG Models iML1515). (1) The text said biomanufacturing "consistently fails" at scale-up and that empirical scale-up campaigns "fail 70-90% of the time." No source gives a failure rate or says failure is consistent; the solicitation speaks of "longstanding barriers to scalability" and of research to "facilitate rapid transition from benchtop to production readiness." The sentences now use those words, and the 70-90% figure is gone, along with the flask and tank volumes in parentheses, which no source gives. (2) "No generalizable framework exists" is not in any source; the sentence now says that predicting which processes will fail, and why, remains the open problem. (3) The text said the US bioeconomy "is valued at over $1 trillion." Neither the Executive Order nor the NSF pages give a valuation; the clause was removed. (4) Biofuels, bioplastics, cell-cultured meat and displacing petroleum-derived chemicals are not in the sources. The sentence now lists the product classes the solicitation names (chemicals, pharmaceuticals, materials, polymers, and fuels) and the Executive Order's link to climate and energy goals and reducing greenhouse gas emissions. (5) "Most promising laboratory strains never become production organisms" and the figures of $50-200 million and 3-5 years for a biopharmaceutical scale-up campaign are in no source; they were removed, and the paragraph now quotes the Executive Order's call to "advance the science of scale-up production while reducing the obstacles for commercialization so that innovative technologies and products can reach markets faster." (6) Invented quotation: the Source Notes said the program supports "fundamental research needed to revitalize American manufacturing." Those words appear on none of the NSF pages read (program page, solicitation, the 2021, 2023 and 2025 award releases, or the February 2026 archived copy of the program page). The note now quotes the program's stated goal verbatim from the program page. (7) The Source Notes dated the FM awards to August 2025; the news release is dated June 24, 2025 (last updated August 22, 2025). The phrase "bioengineering in resource-constrained environments" is in the release word for word. Confirmed in the sources and left as written: the Executive Order's call to expand domestic biomanufacturing capacity across the health, energy, agriculture, and industrial sectors (Sec. 5(a) of the order, repeated on the NSF program page); biomanufacturing as one of the program's three thrust areas; the Cellular and Biochemical Engineering program's support for fundamental research toward "novel bioprocessing and biomanufacturing approaches"; OpenFOAM free under GPL v3; COBRApy pip-installable and GPL-licensed; iML1515 for Escherichia coli K-12 MG1655 downloadable from BiGG Models without an account (the site now answers on https as well as http, and carries a banner saying its data has not been updated since October 2019 and pointing to bigg.bio). Not in any source and left as general background because they carry no number, name or date: the mechanism paragraph (oxygen, pH and nutrient gradients, shear, byproducts, adaptive gene expression) and the "What's Been Tried" account of dimensionless-number scale-up, scale-down models, CFD with metabolic models, minibioreactors, and genome-scale models. The Source line's attribution to the Division of Civil, Mechanical and Manufacturing Innovation matches the ENG/CMMI program officers listed on the solicitation, though the solicitation lists nine sponsoring directorates and offices. No title changed. Genome tags untouched. A second reader went over the repairs on the same day, re-fetching every named source (plus the 2021 and 2023 FM award releases and the archived February 2026 program page); all seven repairs hold as worded, and the second reader corrected one slip in this note: the Executive Order's sectors sentence is in Sec. 5(a) ("Building a Vibrant Domestic Biomanufacturing Ecosystem"), not Sec. 7.